Baxalta (NYSE: BXLT) and Sinovac Biotech (NASDAQ:SVA) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, valuation, dividends and risk.
Valuation & Earnings
This table compares Baxalta and Sinovac Biotech’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Sinovac Biotech||$72.43 million||6.57||-$590,000.00||$0.32||26.09|
Baxalta has higher earnings, but lower revenue than Sinovac Biotech. Baxalta is trading at a lower price-to-earnings ratio than Sinovac Biotech, indicating that it is currently the more affordable of the two stocks.
Baxalta pays an annual dividend of $0.28 per share. Sinovac Biotech does not pay a dividend. Baxalta pays out 23.5% of its earnings in the form of a dividend. Sinovac Biotech has increased its dividend for 2 consecutive years.
This table compares Baxalta and Sinovac Biotech’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings and target prices for Baxalta and Sinovac Biotech, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Institutional and Insider Ownership
31.5% of Sinovac Biotech shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Baxalta beats Sinovac Biotech on 5 of the 9 factors compared between the two stocks.
Baxalta Company Profile
Baxalta Incorporated (Baxalta) is a biopharmaceutical company with a portfolio of differentiated therapies that seek to address medical needs across various disease areas, including hemophilia, immunology and oncology. Baxalta’s categories of products include Hemophilia products, such as Advate, Adynovate, Recombinate, Hemofil M, Immunate, Immunine, Rixubis and Prothromplex Total; Inhibitor Therapies products, including FEIBA and OBIZUR; Immunoglobulin Therapies products, which include GAMMAGARD LIQUID/KIOVIG, HYQVIA, GAMMAGARD S/D and SUBCUVIA; BioTherapeutics products, including FLEXBUMIN, BUMINATE, ARALAST NP, GLASSIA NP and CEPROTIN, and Oncology product, such as ONCASPAR. Baxalta Company develops, manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia.
Sinovac Biotech Company Profile
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company’s pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.
Receive News & Ratings for Baxalta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxalta and related companies with MarketBeat.com's FREE daily email newsletter.